Back to News
Market Impact: 0.25
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
Source: PR Newswire
Healthcare & Biotech
Akeso announced that the first patient has been dosed in the Phase III COMPASSION-40/AK104-313 study of cadonilimab, its PD-1/CTLA-4 bispecific antibody, as monotherapy. This is a clinical-development milestone; the provided article text reports no efficacy results or other study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Merck’s remigromig meets non-inferiority goal in DME trial
- Bank of America is bullish on these top stocks ahead of earnings
- Big Tech is betting $700 billion on AI. Healthcare will decide whether the bet pays off
- Trump’s Medicaid cuts strip health coverage from some legal immigrants—including refugees and victims of human trafficking
- Taiz hospitals near collapse as Houthis tighten siege: Yemen government
- How de-extincting dire wolves and woolly mammoths may extend human life